Hyun-Koo Yoon

Frequencies of CYP3A5 genotypes and haplotypes in a Korean population.

Background and objective:  CYP3A, the drug‐metabolizing enzyme is an important factor in the pharmacokinetics of many drugs. Polymorphism of the CYP3A5 gene is known to influence the functionality of the CYP3A5 enzymes. The full extent of CYP3A5 genetic polymorphism was analysed in a Korean population.

Efficacy of risedronate with cholecalciferol on 25‐hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis

Background  We performed a randomized, double‐blind, prospective, 16‐week clinical trial to evaluate the efficacy and safety of risedronate with and without cholecalciferol on 25‐hydroxyvitamin D [25(OH)D] levels and bone markers in Korean patients with osteoporosis.

Erratum to: Burden of osteoporosis in adults in Korea: a national health insurance database study

An error occurred in the second sentence of the abstract regarding the name of HIRA institution. The correct name is ‘‘Health Insurance Review and Assessment Service’’ instead of ‘‘Health Insurance Review Agency’’. There are errors in the name of authors. The correct names are ‘‘Sunmee Jang’’, ‘‘Suhyun Jang’’ and ‘‘Chanmi Park’’, instead of ‘‘Sun-Mee Jang’’, ‘‘Su-Hyung Jang’’ and ‘‘Chan Mi Park’’, respectively.

Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis

Purpose This study investigated the efficacy and safety of monthly risedronate, with and without cholecalciferol, on 25-hydroxyvitamin D (25[OH]D) levels and bone markers in Korean patients with osteoporosis. Methods A randomized, double-blinded, prospective, 16-week clinical trial was conducted in ten hospitals. A total of 150 subjects with osteoporosis were randomized to one of the two treatment groups: RSDM+ (monthly risedronate 150 mg and cholecalciferol 30,000 IU combined in a single pill, n = 74) or RSDM (monthly risedronate 150 mg alone, n = 76). We measured serum levels of 25-hydroxyvitamin D (25[OH]D), parathyroid hormone (PTH), and bone markers, as well as performing muscle-function tests at baseline and after 16 weeks of treatment. Results After 16 weeks, serum 25(OH)D levels significantly increased from 17.8 to 26.8 ng/mL in the RSDM+ group, but did not change in the RSDM group. The RSDM+ group exhibited significantly decreased serum PTH from 46 to 36.7 pg/mL, while the RSDM group showed a tendency for PTH to increase from 38 to 40.6 pg/mL. In both groups, serum bone-specific alkaline phosphatase and C-terminal telopeptide rapidly declined, with significance at 16 weeks; there were no significant differences between the groups. Conclusion A once-monthly pill of risedronate and cholecalciferol provided equivalent antiresorptive efficacy to risedronate alone in terms of bone turnover and improved 25(OH)D levels over the 16-week treatment period without significant adverse events in Korean patients with osteoporosis.